Research programme: ebola virus vaccines - ReplikinsAlternative Names: Ebola Blocker-Vaccine™; Ebola synthetic Replikins vaccine
Latest Information Update: 09 Jul 2015
At a glance
- Originator Replikins
- Class Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ebola virus infections
Most Recent Events
- 04 Jun 2015 Preclinical trials in Ebola virus infections (Prevention) in USA (Parenteral)
- 28 Aug 2014 Early research in Ebola virus infections (Prevention) in USA (Parenteral)